FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasiliigtoii,	D.C.	20049

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last) C/O BRI	ERSON I (Fi DGEBIO P LING STRE	HARMA, INC.	(Middle)		- B1 3.1 09	2. Issuer Name and Ticker or Trading Symbol BridgeBio Pharma, Inc. [BBIO] 3. Date of Earliest Transaction (Month/Day/Year) 09/01/2020 4. If Amendment, Date of Original Filed (Month/Day/Year)								(Chec	6. Individual or Joint/Group Filing (Check Application) X Form filed by One Reporting Person Form filed by More than One Reportir				
(City)	(S	tate)	(Zip)												Persor				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				Year) if any		A. Deemed xecution Date, any lonth/Day/Year)		action (Instr.	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an		Benefic Owned		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)			(Instr. 4)
Common Stock 09/01/			09/01/2	2020	20			M ⁽¹⁾		10,000	A	\$ <mark>0</mark>	\$0.16		7,751		D		
Common Stock 09/01/202				2020	20		S ⁽¹⁾		5,022	D	\$27.8	27.8938(2) 2		272,729		D			
Common Stock 09/01/202			2020	20			S ⁽¹⁾		4,978	D	\$29.5	529.5805 ⁽³⁾		267,751		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed ion Date, /Day/Year)	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expir	te Exer ration D th/Day/		7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		8	Price of Derivative Security Instr. 5)		Ow For Dire or I (I) (10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	Amo or Num of Shar	ber					
Stock Option (Right to Buy)	\$0.16	09/01/2020			M ⁽¹⁾			10,000	05/19	9/2020	08/26/2028	Commor Stock	10,0	000	\$0.00	9,487		D	

Explanation of Responses:

- 1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020.
- 2. Represents the weighted average sale price of the shares sold from \$27.54 to \$28.35 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.
- 3. Represents the weighted average sale price of the shares sold from \$29.33 to \$29.80 per share.

Remarks:

/s/ Tara Condon, Attorney in

09/02/2020

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.